<DOC>
	<DOCNO>NCT01566786</DOCNO>
	<brief_summary>This trial conduct Asia , Europe Oceania . The aim trial evaluate safety preliminary efficacy activate recombinant human factor VII ( NovoSevenÂ® ) prevent early haematoma growth acute Intracerebral Haemorrhage ( ICH ) .</brief_summary>
	<brief_title>Safety Preliminary Efficacy Activated Recombinant Human Factor VII Acute Intracerebral Haemorrhage</brief_title>
	<detailed_description />
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Cerebral Hemorrhage</mesh_term>
	<mesh_term>Blood Coagulation Disorders</mesh_term>
	<mesh_term>Hemostatic Disorders</mesh_term>
	<criteria>Spontaneous ICH diagnose CT ( Computerized Tomography ) scan within 3 hour onset Signed inform consent form , country waiver informed consent allow IRB/IEC , complete waiver form Time onset symptom ICH unknown 3 hour prior CT Patients secondary ICH related infarction , haemophilia coagulopathy , tumour , trauma , haemorrhagic infarction , cerebrovenous thrombosis , aneurysm , arteriovenous malformation ( AVM ) severe trauma Surgical haematoma evacuation plan perform within 24 hour onset</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>